Quarterly report pursuant to Section 13 or 15(d)

ACQUISITION (Tables)

v3.10.0.1
ACQUISITION (Tables)
9 Months Ended
Sep. 30, 2018
Business Combinations [Abstract]  
Business Acquisition, Pro Forma Information

The following unaudited pro forma consolidated results of operations have been prepared as if the acquisition of Beijing GenExosome had occurred as of the beginning of the following periods:

 

    Three Months Ended     Nine Months Ended  
    September 30, 2017     September 30, 2017  
Net revenues   $ 317,450     $ 758,487  
Net loss   $ (724,801 )   $ (2,222,563 )
Net loss attributable to Avalon GloboCare Corp. common shareholders   $ (719,172 )   $ (2,209,288 )
Net loss per share   $ (0.01 )   $ (0.03 )